(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -3.5% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Amarin's revenue in 2026 is $216,762,000.On average, 4 Wall Street analysts forecast AMRN's revenue for 2026 to be $77,958,952,883, with the lowest AMRN revenue forecast at $73,073,150,520, and the highest AMRN revenue forecast at $82,215,681,979. On average, 4 Wall Street analysts forecast AMRN's revenue for 2027 to be $82,521,830,968, with the lowest AMRN revenue forecast at $65,276,835,850, and the highest AMRN revenue forecast at $99,959,741,888.
In 2028, AMRN is forecast to generate $80,605,254,419 in revenue, with the lowest revenue forecast at $57,610,529,654 and the highest revenue forecast at $104,233,246,272.